<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APAS) commonly presents with cutaneous infarctions mimicking thromboembolic <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">vaso-occlusive disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Systemic anticoagulation is the standard of care for this disorder, but treatment failures can occur </plain></SENT>
<SENT sid="2" pm="."><plain>The authors report the first successful treatment of cutaneous infarctions due to APAS with low-dose, intravenous tissue plasminogen activator (rTPA) in a patient who failed to improve with high-dose anticoagulation </plain></SENT>
<SENT sid="3" pm="."><plain>Wound healing was associated with a marked improvement in blood flow as assessed by scanning laser Doppler </plain></SENT>
<SENT sid="4" pm="."><plain>The authors recommend that patients presenting with cutaneous infarctions in the absence of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> be evaluated for APAS, and that fibrinolytic therapy be considered if cutaneous infarction persists despite <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
</text></document>